PAIC Petra Acquisition, Inc.

Petra Acquisition, Inc.

Business Services

Finance

Petra Acquisition, Inc. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities. The company was incorporated in 2019 and is based in New York, New York.

IPO Year: 2020

Exchange: NASDAQ

Recent Analyst Ratings for Petra Acquisition, Inc.

Date	Price Target	Rating	Analyst

See more ratings

Petra Acquisition, Inc. Press Releases

Fastest customizable press release news feed in the world

Revelation Biosciences Inc. Receives Approval to Initiate Phase 2b Viral Challenge Study of REVTx 99, an Experimental Prophylactic Treatment for the Prevention of Respiratory Viral Infections
- Phase 2b study will investigate the efficacy of REVTx-99 on viral load and patient-reported flu symptoms- - Top-line data anticipated in the second quarter of 2022 - SAN DIEGO, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (Revelation), a clinical-stage life sciences company that is focused on the development of immunologic‑based therapies for the prevention and treatment of disease, announced today it has received approval from the Federal Agency for Medicines and Health Products (FAMHP) and the local Committee of Medical Ethics in Belgium to conduct a Phase 2b influenza viral challenge study. The Phase 2b, randomized, double-blind, influenza viral challenge study (RV
9/28/21 9:00:00 AM ET
$PAIC
Business Services
Finance
Revelation Biosciences, Inc., a Life Sciences Company Developing Therapeutics and Diagnostics for Respiratory Viral Infections, Including COVID-19, to Become Publicly Traded Through a Merger with Petra Acquisition, Inc.
Revelation's lead product candidate REVTx-99 has potential, through innate immune system stimulation, to broadly prevent or treat infections caused by various respiratory viruses such as SARS-CoV-2 including its variants, influenza A and B, parainfluenza, rhinovirus, and respiratory syncytial virus (RSV) Combined company expected to have a post-transaction pro forma total enterprise value of approximately $128 million Merger expected to close in Q4 2021, and combined company will be listed on NASDAQ under the ticker symbol "REVB" Revelation and Petra Acquisition will host a joint investor conference call and webcast to discuss the proposed transaction on August 30, 2021 at 4:30 p.m
8/30/21 6:00:00 AM ET
$PAIC
Business Services
Finance
PETRA ACQUISITION, INC. RECEIVES EXPECTED NASDAQ NOTIFICATION REGARDING DELAYED FORM 10-Q
New York, NY, June 01, 2021 (GLOBE NEWSWIRE) -- Petra Acquisition, Inc. (NASDAQ:PAIC) (the "Company"), a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities, announced that on May 28, 2021, it received a letter from the Listing Qualifications Department of the Nasdaq Stock Market ("Nasdaq") advising that because the Company failed to timely file its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2021 (the "Form 10-Q"), the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Rule"). Nasdaq has inform
6/1/21 4:30:00 PM ET
$PAIC
Business Services
Finance

Petra Acquisition, Inc. Market Insights

Live Market Insights

EXCLUSIVE: New On NASDAQ Deck, Revelation Bio's COVID-19 Antiviral Shows Encouraging Preclinical Action
Revelation Biosciences Inc (NASDAQ:REVB) says that it observed a significant decrease in viral load with the prophylactic treatment of REVTx-99 in models of COVID-19 infection. What Happened: REVTx-99 was assessed for prophylactic antiviral activity against delta variant infection in three separate cell lines. Each cell line expressed sufficient levels of ACEII and TLR4, receptors required to sufficiently demonstrate viral infection as well as REVTx-99 activity, respectively. Why It Matters: Human primary bronchial/tracheal and alveolar epithelial cells were treated with 250 nanograms per mL (ng/mL) REVTx-99 one hour and 24 hours before infection, respectively. In both the cell lines, vi
1/11/22 8:55:49 AM ET
$PAIC
Business Services
Finance
New On NASDAQ Deck, Revelation Bio's COVID-19 Antiviral Shows Encouraging Preclinical Action
Revelation Biosciences Inc (NASDAQ:REVB) says that it observed a significant decrease in viral load with the prophylactic treatment of REVTx-99 in models of COVID-19 infection. What Happened: REVTx-99 was assessed for prophylactic antiviral activity against delta variant infection in three separate cell lines. Each cell line expressed sufficient levels of ACEII and TLR4, receptors required to sufficiently demonstrate viral infection as well as REVTx-99 activity, respectively. Why It Matters: Human primary bronchial/tracheal and alveolar epithelial cells were treated with 250 nanograms per mL (ng/mL) REVTx-99 one hour and 24 hours before infection, respectively. In both the cell lines, vi
1/11/22 8:00:12 AM ET
$PAIC
Business Services
Finance
Stocks That Hit 52-Week Lows On Thursday
On Thursday, 615 stocks hit new 52-week lows. Noteable 52-Week Lows And Highs: Sea (NYSE:SE) is the largest company in terms of market cap to set a new 52-week low this morning. The smallest company by market cap to hit a new 52-week low was Reshape Lifesciences (NASDAQ:RSLS). Aligos Therapeutics (NASDAQ:ALGS) saw the largest move of the companies, as shares plummetted 46.75% to hit a new 52-week low. Vimeo (NASDAQ:VMEO) shares were the most resilient, as shares rose 0.0%, rebounding from its new 52-week low. The following stocks created new 52-week lows as of 10am on Thursday: Rivian Automotive (NASDAQ:RIVN) stock achieved a new 52-week low on Thursday morning, hitting $75
1/6/22 12:14:13 PM ET
$SOS
$SPCE
$SPI
$SPIR
Finance: Consumer Services
Finance
Transportation Services
Consumer Discretionary
Stocks That Breached 52-Week Lows Today
Stocks That Managed to Breach 52-Week Lows Tuesday Morning Before 10 am Tuesday, 44 stocks made new 52-week lows. 52-Week High And Low Highlights: Block (NYSE:SQ) was the biggest company on a market cap basis to set aStocks That Managed to Breach 52-Week Lows Tuesday Morning Before 10 am Tuesday, 44 stocks made new 52-week lows. 52-Week High And Low Highlights: Block (NYSE:SQ) was the biggest company on a market cap basis to set a new 52-week low. Shineco (NASDAQ:SISI) was the smallest company in terms of market cap to set a new 52-week low. Avrobio (NASDAQ:AVRO) made the largest move down on the session, with shares plummeting 36.88% to reach its 52-week low. Pathfinder Acquisition (NASDA
1/4/22 10:31:34 AM ET
$APPN
$AVRO
$BILI
$BKKT
Computer Software: Prepackaged Software
Technology
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

Petra Acquisition, Inc.

Recent Analyst Ratings for Petra Acquisition, Inc.

Petra Acquisition, Inc.

Recent Analyst Ratings for Petra Acquisition, Inc.

Petra Acquisition, Inc. Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4: Feis Lawrence disposed of $7,465,890 worth of shares (731,950 units at $10.20)

SEC Form 3: New insider Feis Lawrence claimed ownership of 746,491 shares

SEC Form 4: Glazer Capital, Llc sold $6,597,824 worth of Common stock (654,546 units at $10.08)

SEC Form 3: Howard William Carson claimed ownership of 10,000 units of Common Stock

Petra Acquisition, Inc. Financials

Live finance-specific insights

Revelation Biosciences, Inc., a Life Sciences Company Developing Therapeutics and Diagnostics for Respiratory Viral Infections, Including COVID-19, to Become Publicly Traded Through a Merger with Petra Acquisition, Inc.

Petra Acquisition, Inc. Press Releases

Fastest customizable press release news feed in the world

Revelation Biosciences Inc. Receives Approval to Initiate Phase 2b Viral Challenge Study of REVTx 99, an Experimental Prophylactic Treatment for the Prevention of Respiratory Viral Infections

Revelation Biosciences, Inc., a Life Sciences Company Developing Therapeutics and Diagnostics for Respiratory Viral Infections, Including COVID-19, to Become Publicly Traded Through a Merger with Petra Acquisition, Inc.

PETRA ACQUISITION, INC. RECEIVES EXPECTED NASDAQ NOTIFICATION REGARDING DELAYED FORM 10-Q

Petra Acquisition, Inc. SEC Filings

Petra Acquisition, Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

Petra Acquisition, Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits

Petra Acquisition, Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

SEC Form DEFA14A filed by Petra Acquisition, Inc.

Petra Acquisition, Inc. filed SEC Form 8-K: Other Events

SEC Form 424B3 filed by Petra Acquisition, Inc.

SEC Form EFFECT filed by Petra Acquisition, Inc.

SEC Form S-4/A filed by Petra Acquisition, Inc. (Amendment)

SEC Form S-4/A filed by Petra Acquisition, Inc. (Amendment)

Petra Acquisition, Inc. Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G/A filed by Petra Acquisition, Inc. (Amendment)

SEC Form SC 13G/A filed by Petra Acquisition, Inc. (Amendment)

SEC Form SC 13G/A filed by Petra Acquisition, Inc. (Amendment)

SEC Form SC 13G filed by Petra Acquisition, Inc.

SEC Form SC 13G filed by Petra Acquisition, Inc.

SEC Form SC 13G filed

SEC Form SC 13G filed

SEC Form SC 13G/A filed

SEC Form SC 13G/A filed

Petra Acquisition, Inc. Market Insights

Live Market Insights

EXCLUSIVE: New On NASDAQ Deck, Revelation Bio's COVID-19 Antiviral Shows Encouraging Preclinical Action

New On NASDAQ Deck, Revelation Bio's COVID-19 Antiviral Shows Encouraging Preclinical Action

Stocks That Hit 52-Week Lows On Thursday

Stocks That Breached 52-Week Lows Today